Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?

Purpose of Review The pathogenesis of DILI is currently unknown; however, research has shown strong genetic associations with some DILIs. This paper describes the variant alleles uncovered by GWAS and discusses their potential role as susceptibility biomarkers. Recent Findings An association with HL...

Full description

Saved in:
Bibliographic Details
Published in:Current hepatology reports 2017, Vol.16 (3), p.258-264
Main Authors: Clare, Kathleen E., Miller, Michael H., Dillon, John F.
Format: Article
Language:English
Subjects:
Drug-Induced Liver Injury (F Bessone and R Andrade
Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)
Hepatology
Medicine
Medicine & Public Health
Section Editors
Topical Collection on Drug-Induced Liver Injury
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review The pathogenesis of DILI is currently unknown; however, research has shown strong genetic associations with some DILIs. This paper describes the variant alleles uncovered by GWAS and discusses their potential role as susceptibility biomarkers. Recent Findings An association with HLADRB1*15:01 and amoxicillin/clavulanate DILI has been shown by a number of research groups. The presence of the HLA-B*57:01 allele has been associated with an 81-fold increased risk of flucloxacillin DILI. The HLA-B*35:02 allele has significant association with minocycline DILI. Summary With the exception of abacavir for HIV therapy, no other prospective genetic screening tests have met the threshold for clinical application. This is largely because DILI incidence is too low to warrant the cost and effort associated with testing. Perhaps, with the development of personalised medicine, a panel of genes for disease susceptibility, drug efficacy and adverse reactions could be tested once off. This would change the cost-effectiveness paradigm, personalise healthcare and reduce DILI risk by avoiding medications in patients with specific HLA alleles.
ISSN:2195-9595
2195-9595
DOI:10.1007/s11901-017-0363-9